{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:42:44Z","timestamp":1792510964784,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>To explore whether Methamphetamine-related disorders (MRDs) will cause the risk of cardiomyopathy in the future. This study used Taiwan\u2019s Longitudinal Generation Tracking Database (LGTD) to conduct a 1:4 paired analysis of sex, age, and inclusion year. 17,071 patients with MRDs and 153 patients with cardiomyopathy were selected; 68,264 patients without MRDs and 274 patients with cardiomyopathy were also selected. This study used SPSS 22 statistical software to conduct Cox regression analysis. Patients with MRDs had a 3.421-folds higher risk of cardiomyopathy than patients without MRDs. Men have a 0.735-fold lower risk of developing cardiomyopathy than women. In terms of age group, aged 50\u201364 and \u2267\u200965 have a 1.145- and 1.332-folds higher risk of cardiomyopathy, respectively, compared to those aged 20\u201349. For each one-point increase in Charlson Comorbidity Index (CCI), the risk of cardiomyopathy rises by 58.3%. Specifically, for three types of Methamphetamines (Methamphetamine and other psychostimulant dependence, Methamphetamine or related acting sympathomimetic abuse, Methamphetamine psychosis), the HR for cardiomyopathy in patients with MRDs was 3.864 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), 2.916 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and 2.295 (<jats:italic>p<\/jats:italic>\u2009=\u20090.016) times higher, respectively, compared to patients without MRDs. The Kaplan-Meier log-rank test was used to calculate the cumulative risk of MRDs, showing a significant difference in the cumulative cardiomyopathy incidence between the MRDs and non-MRDs groups (long-rank test, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). MRDs will increase the risk of cardiomyopathy. Women are more susceptible to cardiomyopathy than men, and the risk escalates for individuals aged 50\u201364 and those 65 years or older, compared to the 20\u201349-year age group. Additionally, an increase in the CCI correlates with a heightened risk of cardiomyopathy. There are important differences between these groups in terms of duration, frequency, and severity of use, with longer exposure and more frequent use increasing the risk of dependence and psychosis, but individual susceptibility, dose, and use patterns also play key roles.<\/jats:p>","DOI":"10.1038\/s41598-025-94591-0","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T22:04:38Z","timestamp":1743804278000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Increased risk of cardiomyopathy in individuals with methamphetamine related disorders in Taiwan"],"prefix":"10.1038","volume":"15","author":[{"given":"Pi-Ching","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho-Tsung","family":"Hsin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ting","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Ching","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Hao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsu-Hsuan","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing\u2011Long","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Hsiang","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Yun","family":"Fann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu-Chien","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Sen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"94591_CR1","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/jhmas\/jrj039","volume":"61","author":"N Rasmussen","year":"2006","unstructured":"Rasmussen, N. Making the first anti-depressant: amphetamine in American medicine, 1929\u20131950. J. Hist. Med. Allied Sci. 61, 288\u2013323 (2006).","journal-title":"J. Hist. Med. Allied Sci."},{"key":"94591_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.disamonth.2011.09.004","volume":"58","author":"D Vearrier","year":"2012","unstructured":"Vearrier, D., Greenberg, M. I., Miller, S. N., Okaneku, J. T. & Haggerty, D. A. Methamphetamine: history, pathophysiology, adverse health effects, current trends, and hazards associated with the clandestine manufacture of methamphetamine. Dis. Mon.  58, 38\u201389 (2012).","journal-title":"Dis. Mon."},{"key":"94591_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/bs.irn.2015.02.001","volume":"120","author":"N Rasmussen","year":"2015","unstructured":"Rasmussen, N. Amphetamine-type stimulants: the early history of their medical and non\u2010medical uses. Int. Rev. Neurobiol. 120, 9\u201325 (2015).","journal-title":"Int. Rev. Neurobiol."},{"key":"94591_CR4","unstructured":"Centers for Disease Control and Prevention.  Centers for Disease Control and Prevention: FastStats: Illegal drug use (2022). https:\/\/www.cdc.gov\/nchs\/fastats\/drug-use-illicit.htm."},{"key":"94591_CR5","unstructured":"National Institute on Drug Abuse. What is the scope of methamphetamine use in the United. https:\/\/nida.nih.gov\/publications\/research-reports\/methamphetamine\/what-scope-methamphetamine-misuse-in-united-states (2024)."},{"key":"94591_CR6","unstructured":"Science, X.  Medical xpress: prevalence of Meth heart failure now seen in a wide range of socioeconomic and Racial groups (2022). https:\/\/medicalxpress.com\/news\/2022-12-prevalence-meth-heart-failure-wide.html."},{"key":"94591_CR7","doi-asserted-by":"publisher","unstructured":"Kevil, C. G., Goeders, N. E., Woolard, M. D. et al. 7.\tMethamphetamine use and cardiovascular disease. Arterioscler Thromb. Vasc. Biol.  39, 1739\u20131746. https:\/\/doi.org\/10.1161\/ATVBAHA.119.312461 (2019).","DOI":"10.1161\/ATVBAHA.119.312461"},{"issue":"8","key":"94591_CR8","doi-asserted-by":"publisher","first-page":"e43854","DOI":"10.7759\/cureus.43854","volume":"15","author":"Y Breier","year":"2023","unstructured":"Breier, Y., Azrak, E., Banks, W., Kushmakov, R. & Aleshinskaya, I. Management of new onset Amphetamine-Induced acute decompensated heart failure in a young adult: case report. Cureus 15(8), e43854. https:\/\/doi.org\/10.7759\/cureus.43854 (2023).","journal-title":"Cureus"},{"key":"94591_CR9","doi-asserted-by":"publisher","unstructured":"Lucy Chapman, I. et al. Amphetamine-induced cardiomyopathy complicated by embolic stroke: a case report. Eur. Heart J. Case Rep. 6(2), ytac044. https:\/\/doi.org\/10.1093\/ehjcr\/ytac044  (2020).","DOI":"10.1093\/ehjcr\/ytac044"},{"issue":"12","key":"94591_CR10","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/clc.22195","volume":"36","author":"S Won","year":"2013","unstructured":"Won, S., Hong, R. A., Shohet, R. V., Seto, T. B. & Parikh, N. I. Methamphetamine-associated cardiomyopathy. Clin. Cardiol. 36(12), 737\u2013742 (2013).","journal-title":"Clin. Cardiol."},{"issue":"14","key":"94591_CR11","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1161\/CIRCULATIONAHA.106.174287","volume":"113","author":"BJ Maron","year":"2006","unstructured":"Maron, B. J. et al. Contemporary definitions and classification of the cardiomyopathies: an American heart association scientific statement from the Council on clinical cardiology, heart failure and transplantation committee; quality of care and outcomes research and functional genomics and translational biology interdisciplinary working groups; and Council on epidemiology and prevention. Circulation 113(14), 1807\u20131816 (2006).","journal-title":"Circulation"},{"issue":"10","key":"94591_CR12","first-page":"640","volume":"96","author":"J Brieler","year":"2017","unstructured":"Brieler, J., Breeden, M. A. & Tucker, J. Cardiomyopathy: an overview. Am. Family Phys. 96(10), 640\u2013646 (2017).","journal-title":"Am. Family Phys."},{"issue":"5","key":"94591_CR13","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/ejhf.1461","volume":"21","author":"PM Seferovi\u0107","year":"2019","unstructured":"Seferovi\u0107, P. M. et al. Heart failure in cardiomyopathies: a position paper from the heart failure association of the European society of cardiology. Eur. J. Heart Fail. 21(5), 553\u2013576 (2019).","journal-title":"Eur. J. Heart Fail."},{"issue":"2","key":"94591_CR14","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/MNH.0000000000000099","volume":"24","author":"K Tsuruya","year":"2015","unstructured":"Tsuruya, K. & Eriguchi, M. Cardiorenal syndrome in chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 24(2), 154\u2013162 (2015).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"issue":"1","key":"94591_CR15","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/ki.1995.22","volume":"47","author":"RN Foley","year":"1995","unstructured":"Foley, R. N. et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 47(1), 186\u2013192 (1995).","journal-title":"Kidney Int."},{"issue":"1","key":"94591_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1146\/annurev-psych-122414-033457","volume":"67","author":"BJ Everitt","year":"2016","unstructured":"Everitt, B. J. & Robbins, T. W. Drug addiction: updating actions to habits to compulsions ten years on. Ann. Rev. Psychol. 67(1), 23\u201350 (2016).","journal-title":"Ann. Rev. Psychol."},{"issue":"6","key":"94591_CR17","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.pneurobio.2005.04.003","volume":"75","author":"D Sulzer","year":"2005","unstructured":"Sulzer, D., Sonders, M. S., Poulsen, N. W. & Galli, A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog. Neurobiol. 75(6), 406\u2013433 (2005).","journal-title":"Prog. Neurobiol."},{"issue":"6","key":"94591_CR18","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1177\/08971900221110453","volume":"36","author":"C Herbst","year":"2023","unstructured":"Herbst, C., O\u2019Connell, M., Melton, B. L. & Moeller, K. E. Initiation of antipsychotic treatment for amphetamine induced psychosis and its impact on length of stay. J. Pharm. Pract. 36(6), 1324\u20131329 (2023).","journal-title":"J. Pharm. Pract."},{"issue":"1\u20132","key":"94591_CR19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.drugalcdep.2012.10.001","volume":"129","author":"JK Cunningham","year":"2013","unstructured":"Cunningham, J. K. et al. Mexico\u2019s precursor chemical controls: emergence of less potent types of methamphetamines in the united States. Drug Alcohol Depend. 129(1\u20132), 125\u2013136 (2013).","journal-title":"Drug Alcohol Depend."},{"key":"94591_CR20","doi-asserted-by":"crossref","unstructured":"Guzik, T. J. et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc. Res. 116(10), 1666\u20131687 (2020).","DOI":"10.1093\/cvr\/cvaa106"},{"issue":"12","key":"94591_CR21","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s41371-022-00707-8","volume":"36","author":"H Goel","year":"2022","unstructured":"Goel, H., Shah, K., Kumar, A., Hippen, J. T. & Nadar, S. K. Temperature, cardiovascular mortality, and the role of hypertension and renin\u2013angiotensin\u2013aldosterone axis in seasonal adversity: a narrative review. J. Hum. Hypertens. 36(12), 1035\u20131047 (2022).","journal-title":"J. Hum. Hypertens."},{"key":"94591_CR22","doi-asserted-by":"publisher","unstructured":"Segawa, T., Arita, Y., Ogasawara, N. & Hasegawa, S. Hypertensive heart disease associated with methamphetamine abuse. J. Cardiol. Cases 19, 47\u201350.  https:\/\/doi.org\/10.1016\/j.jccase.2018.10.001. (2019).","DOI":"10.1016\/j.jccase.2018.10.001"},{"key":"94591_CR23","unstructured":"Qutrio et al. Methamphetamine-induced cardiomyopathy (MACM) in a middle-aged man; a case report.  https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5827055\/Emerg(Tehran);6:0  (2018)."},{"issue":"9","key":"94591_CR24","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.3390\/biom13091409","volume":"13","author":"H Dridi","year":"2023","unstructured":"Dridi, H. et al. Mitochondrial calcium overload plays a causal role in oxidative stress in the failing heart. Biomolecules 13(9), 1409. https:\/\/doi.org\/10.3390\/biom13091409 (2023).","journal-title":"Biomolecules"},{"key":"94591_CR25","doi-asserted-by":"publisher","unstructured":"Chapman, L., Khalifa, I., Sheriff, N. & Colwell, N. Amphetamine-induced cardiomyopathy complicated by embolic stroke: a case report. Eur. Heart J. Case Rep.  6(2), ytac044. https:\/\/doi.org\/10.1093\/ehjcr\/ytac044   (2022).","DOI":"10.1093\/ehjcr\/ytac044"},{"key":"94591_CR26","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1161\/ATVBAHA.119.312461","volume":"39","author":"C Kevil","year":"2019","unstructured":"Kevil, C. et al. Methamphetamine use and cardiovascular disease. Arterioscler. Thromb. Vasc Biol. 39, 1739\u20131746 (2019).","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"key":"94591_CR27","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1002\/med.21476","volume":"38","author":"P Mlad\u011bnka","year":"2018","unstructured":"Mlad\u011bnka, P. et al. TOX-OER and CARDIOTOX Hradec Kr\u00e1lov\u00e9 researchers and collaborators. Comprehensive review of cardiovascular toxicity of drugs and related agents. Med. Res. Rev. 38, 1332\u20131403 (2018).","journal-title":"Med. Res. Rev."},{"key":"94591_CR28","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1111\/j.1360-0443.2007.01874.x","volume":"102","author":"S Kaye","year":"2007","unstructured":"Kaye, S., McKetin, R., Duflou, J. & Darke, S. Methamphetamine and cardiovascular pathology: a review of the evidence. Addiction 102, 1204\u20131211 (2007).","journal-title":"Addiction"},{"key":"94591_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jacc.2010.02.047","volume":"56","author":"C Jellis","year":"2010","unstructured":"Jellis, C., Martin, J., Narula, J. & Marwick, T. H. Assessment of nonischemic myocardial fibrosis. J. Am. Coll. Cardiol. 56, 89\u201397 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"key":"94591_CR30","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.ajem.2018.01.001","volume":"36","author":"JR Richards","year":"2018","unstructured":"Richards, J. R., Harms, B. N., Kelly, A. & Turnipseed, S. D. Methamphetamine use and heart failure: prevalence, risk factors, and predictors. Am. J. Emerg. Med. 36, 1423\u20131428 (2018).","journal-title":"Am. J. Emerg. Med."},{"issue":"2","key":"94591_CR31","doi-asserted-by":"publisher","first-page":"CD003021","DOI":"10.1002\/14651858.CD003021.pub2","volume":"2009","author":"SJ Shoptaw","year":"2009","unstructured":"Shoptaw, S. J., Kao, U., Heinzerling, K. & Ling, W. Treatment for amphetamine withdrawal. Cochrane Database Syst. Rev. 2009(2), CD003021. https:\/\/doi.org\/10.1002\/14651858.CD003021.pub2 (2009).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"94591_CR32","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40263-020-00711-x","volume":"34","author":"KJ Siefried","year":"2020","unstructured":"Siefried, K. J., Acheson, L. S., Lintzeris, N. & Ezard, N. Pharmacological treatment of methamphetamine\/amphetamine dependence: a systematic review. CNS Drugs 34(4), 337\u2013365. https:\/\/doi.org\/10.1007\/s40263-020-00711-x (2020).","journal-title":"CNS Drugs"},{"issue":"1","key":"94591_CR33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.amjcard.2019.09.030","volume":"125","author":"SX Zhao","year":"2020","unstructured":"Zhao, S. X., Seng, S., Deluna, A., Yu, E. C. & Crawford, M. H. Comparison of clinical characteristics and outcomes of patients with reversible versus persistent Methamphetamine-Associated cardiomyopathy. Am. J. Cardiol. 125(1), 127\u2013134 (2020).","journal-title":"Am. J. Cardiol."},{"key":"94591_CR34","doi-asserted-by":"crossref","unstructured":"Kaye, S., McKetin, R. & Duflou, J. Methamphetamine and cardiovascular pathology: a review of the evidence. Addiction 102, 1204\u20131211 (2007).","DOI":"10.1111\/j.1360-0443.2007.01874.x"},{"key":"94591_CR35","doi-asserted-by":"crossref","unstructured":"Yeo, K.-K., Wijetunga, M. & Ito, H. The association of methamphetamine use and cardiomyopathy in young patients. Am. J. Med.   120, 165\u2013171 (2007).","DOI":"10.1016\/j.amjmed.2006.01.024"},{"key":"94591_CR36","doi-asserted-by":"crossref","unstructured":"Wijetunga, M., Seto, T. & Lindsay, J. Crystal methamphetamine-associated cardiomyopathy:tip of the iceberg? J. Toxicol. Clin. Toxicol.  41, 981\u2013986 (2003).","DOI":"10.1081\/CLT-120026521"},{"key":"94591_CR37","doi-asserted-by":"crossref","unstructured":"Sch\u00fcrer, S.,   Klingel, K. & Sandri, M.  Clinical characteristics, histopathological features, and clinical outcome of methamphetamine-associated cardiomyopathy. JACC Heart Fail.  5, 435\u2013445 (2017).","DOI":"10.1016\/j.jchf.2017.02.017"},{"key":"94591_CR38","doi-asserted-by":"crossref","unstructured":"Ito, H.,   Yeo, K.-K. & Wijetunga, M. A comparison of echocardiographic findings in young adults with cardiomyopathy: with and without a history of methamphetamine abuse. Clin. Cardiol.  32, E18\u2013E22 (2009).","DOI":"10.1002\/clc.20367"},{"key":"94591_CR39","doi-asserted-by":"crossref","unstructured":"Won, S., Hong, R. A. & Shohet, R. V. Methamphetamine-associated cardiomyopathy. Clin. Cardiol. 36, 737\u2013742 (2013).","DOI":"10.1002\/clc.22195"},{"key":"94591_CR40","doi-asserted-by":"crossref","unstructured":"Jafari Giv, M. Exposure to amphetamines leads to development of Amphetamine Type Stimulants Associated Cardiomyopathy (ATSAC). Cardiovasc. Toxicol.  17, 13\u201324 (2017).","DOI":"10.1007\/s12012-016-9385-8"},{"key":"94591_CR41","doi-asserted-by":"crossref","unstructured":"Zhao, S. X., Kwong, C. & Swaminathan, A. et al.  Clinical characteristics and outcome of methamphetamine-associated pulmonary arterial hypertension and dilated cardiomyopathy. JACC Heart Fail. 6, 209\u2013218 (2018).","DOI":"10.1016\/j.jchf.2017.10.006"},{"issue":"16","key":"94591_CR42","doi-asserted-by":"publisher","first-page":"e023663","DOI":"10.1161\/JAHA.121.023663","volume":"11","author":"L Curran","year":"2022","unstructured":"Curran, L. et al. Clinical correlates and outcomes of Methamphetamine-Associated cardiovascular diseases in hospitalized patients in California. J. Am. Heart Assoc. 11(16), e023663. https:\/\/doi.org\/10.1161\/JAHA.121.023663 (2022).","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"94591_CR43","doi-asserted-by":"publisher","first-page":"18933","DOI":"10.1038\/s41598-021-98026-4","volume":"11","author":"S Kim","year":"2021","unstructured":"Kim, S. et al. The Charlson comorbidity index is associated with risk of 30-day mortality in patients with myocardial injury after non-cardiac surgery. Sci. Rep. 11(1), 18933. https:\/\/doi.org\/10.1038\/s41598-021-98026-4 (2021).","journal-title":"Sci. Rep."},{"key":"94591_CR44","unstructured":"Martin, D. & Le, J. K. Amphetamine.  In StatPearls [Internet]  (StatPearls Publishing, 2024).   https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK556103\/. Accessed 31 Jul 2023."},{"issue":"8","key":"94591_CR45","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1002\/acn3.51113","volume":"7","author":"NS Tzeng","year":"2020","unstructured":"Tzeng, N. S. et al. Association between amphetamine-related disorders and dementia-a nationwide cohort study in Taiwan. Ann. Clin. Transl Neurol. 7(8), 1284\u20131295. https:\/\/doi.org\/10.1002\/acn3.51113 (2020).","journal-title":"Ann. Clin. Transl Neurol."},{"key":"94591_CR46","unstructured":"Ministry of Health and Welfare. The Annual of Statistical Data of Cases and Laboratory Examinations for the Drug Abuse 2018: Taiwan Food and Drug Administration, Ministry of Health and Welfare (2018)."},{"key":"94591_CR47","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.neuroimage.2008.07.020","volume":"43","author":"JS Fowler","year":"2008","unstructured":"Fowler, J. S. et al. Fast uptake and long-lasting binding of methamphetamine in the human brain: comparison with cocaine. NeuroImage 43, 756\u2013763 (2008).","journal-title":"NeuroImage"},{"key":"94591_CR48","first-page":"301","volume":"31","author":"AM Barr","year":"2006","unstructured":"Barr, A. M. et al. The need for speed: an update on methamphetamine addiction. J. Psychiatry Neurosci. 31, 301\u2013313 (2006).","journal-title":"J. Psychiatry Neurosci."},{"issue":"2","key":"94591_CR49","doi-asserted-by":"publisher","first-page":"102355","DOI":"10.1016\/j.cpcardiol.2023.102355","volume":"49","author":"A Raja","year":"2024","unstructured":"Raja, A. et al. Trends in substance-induced cardiomyopathy-related mortality among older adults in the united States from 1999 to 2020. Curr. Probl. Cardiol. 49(2), 102355 (2024).","journal-title":"Curr. Probl. Cardiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94591-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94591-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94591-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T20:02:53Z","timestamp":1747425773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94591-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["94591"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-94591-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this Article was revised: In the original version of this Article, Wu-Chien Chien and Sung-Sen Yang were incorrectly affiliated with \u201cDepartment of Medical Research, Tri-Service General Hospital, National Defense Medical Center, 7115R, No.325, Section 2, Cheng-Kung Road, Nei-hu District, Taipei City 11490, Taiwan\u201d.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The correct affiliations for Wu-Chien Chien are \u2018Graduate Institute of Medicine, National Defense Medical Center, Taipei 11490, Taiwan\u2019, \u2018Department of Medical Research, Tri-Service General Hospital, Taipei 11490, Taiwan\u2019, \u2018School of Public Health, National Defense Medical Center, Taipei 11490, Taiwan\u2019, \u2018Taiwanese Injury Prevention and Safety Promotion Association (TIPSPA), Taipei 11490, Taiwan\u2019 and \u2018Graduate Institute of Life Sciences, National Defense Medical Center, Taipei 11490, Taiwan\u2019. The correct affiliations for Sung-Sen Yang are \u2018Graduate Institute of Medicine, National Defense Medical Center, Taipei 11490, Taiwan\u2019 and \u2018Department of Nephrology, Tri-Service General Hospital, Taipei 11490, Taiwan\u2019.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article has been corrected.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted according to the Code of Ethics of the World Medical Association (Declaration of Helsinki). The Institutional Review Board of the Tri-Service General Hospital approved this study (TSGHIRB No. E202416046)) and waived the need for individual consent since all the identification data were encrypted in the NHIRD.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"11449"}}